Leap Therapeutics Announces $58.88M Private Placement

Leap Therapeutics ( (LPTX) ) has shared an announcement.

On October 6, 2025, Leap Therapeutics announced a $58.88 million private placement led by Winklevoss Capital to initiate a digital asset treasury strategy. This move aims to build long-term shareholder value through active participation in digital assets, while also continuing the development of its therapeutic programs. The private placement includes the sale of shares and warrants, with Winklevoss Capital gaining board representation. The closing of the private placement is expected around October 8, 2025, subject to customary conditions.

The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.

Spark’s Take on LPTX Stock

According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.

Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.

To see Spark’s full report on LPTX stock, click here.

More about Leap Therapeutics

Leap Therapeutics is a biotechnology company focused on developing targeted and immuno-oncology therapeutics. Its pipeline includes sirexatamab, a humanized monoclonal antibody targeting the Dickkopf-1 protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 protein.

Average Trading Volume: 1,487,108

Technical Sentiment Signal: Sell

Current Market Cap: $22.11M

Find detailed analytics on LPTX stock on TipRanks’ Stock Analysis page.